Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect of ABP-671 in Healthy Subjects
NCT04303039Phase 1Completed
- Sponsor
- Atom Therapeutics
- Start
- May 2020
- Primary completion
- Jun 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lingdolinurad in gout and hyperuricemia (2 arms), sponsored by Atom Therapeutics. Primary endpoint: Plasma ABP-671 Concentration at 72 hours. Started May 2020; status: completed.
02
Drugs
lingdolinurad
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on NCT04303039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04303039.